Pharmacological characterization of the leukocyte kinetics after intranasal antigen challenge in a guinea pig model of allergic rhinitis

Inflammation Research

Volumn 50, Issue 9, 2001, Pages 474-482

  Yamasaki, M ^a,b   Sasaki, K ^b   Mizutani, N ^b   Nabe, T ^b   Sakura, Y ^a   Matsumoto, T ^a   Ashida, Y ^a   Kohno, S ^b  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

^b KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Allergic rhinitis; Eosinophil; Histamine; Peptide leukotrienes; Thromboxane A2

Indexed keywords

ANTIGEN; ANTIHISTAMINIC AGENT; DEXAMETHASONE; GLUCOCORTICOID; LEUKOTRIENE RECEPTOR BLOCKING AGENT; PRANLUKAST; SERATRODAST; TERFENADINE; THROMBOXANE A2 RECEPTOR BLOCKING AGENT;

ALLERGIC RHINITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; ARTICLE; CELL KINETICS; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; EOSINOPHILIA; GUINEA PIG; HISTOPATHOLOGY; LAVAGE; LEUKOCYTE COUNT; MALE; NONHUMAN; NOSE SMEAR; POLLEN ALLERGY;

EID: 0034834681     PISSN: 10233830     EISSN: None     Source Type: Journal    
DOI: 10.1007/PL00000273     Document Type: Article

References (36)

1. Eosinophilia
2. The influx of inflammatory cells into nasal washings during the late response to antigen challenge. Effect of systemic steroid pretreatment
3. Biochemical properties of eosinophils and their preferential accumulation mechanism in nasal allergy
4. Circulating eosinophil/basophil progenitors and nasal mucosal cytokines in seasonal allergic rhinitis
5. Mechanisms of eosinophil-associated inflammation
6. Development of pollen-induced allergic rhinitis with early and late phase nasal blockage in guinea pigs
7. Nasal hyperresponsiveness to histamine induced by repetitive exposure to cedar pollen in guinea-pigs
8. Evaluation of threshold criteria for the nasal histamine challenge test in perennial allergic rhinitis
9. 2 and peptide leukotrienes in early and late phase nasal blockage in a guinea pig model of allergic rhinitis
10. 2 receptor antagonist, ramatroban (BAY u 3405), on inflammatory cells, chemical mediators and non-specific nasal hyperreactivity after allergen challenge in patients with perennial allergic rhinitis
11. 4-receptor antagonist, ICI 204,219, relieves symptoms of acute seasonal allergic rhinitis
12. 1-receptor antagonists: Clinical pharmacology and therapeutics
13. 2 receptor by anti-asthmatic agent AA-2414
14. Inhibitory effect of ONO-1078 on specific binding of peptide leukotrienes to human lung crude membrane
15. Terfenadine, the first non-sedating antihistamine
16. Comparative studies on nebulizers for antigen inhalation in experimental asthma
17. A new model of experimental allergic rhinitis using Japanese cedar pollen in guinea pigs
18. 2 and histamine in experimental allergic rhinitis of guinea pigs
19. In vivo pharmacological profile of ONO-1078: A potent, selective and orally active peptide leukotriene (LT) antagonist
20. 1 receptor antagonist, KAA-276
21. Comparison of rhinomanometry, symptom score, and inflammatory cell counts in assessing the nasal latephase reaction to allergen challenge
22. Dynamics of nasal eosinophils in response to a nonnatural allergen challenge in patients with allergic rhinitis and control subjects: A biopsy and brush study
23. Use of nasal steroids in managing allergic rhinitis
24. 2 receptor antagonist (Bay u 3405) on nasal symptoms after antigen challenge in sensitized guinea pigs
25. Involvement of cysteinyl leukotrienes in biphasic increase of nasal airway resistance of antigen-induced rhinitis in guinea pigs
26. Mechanism of topical glucocorticoid treatment of hay fever: IL-5 and eosinophil activation during natural allergen exposure are suppressed, but IL-4, IL-6, and IgE antibody production are unaffected
27. Eotaxin mRNA and protein expression in chronic sinusitis and allergen-induced nasal responses in seasonal allergic rhinitis
28. 2 receptor antagonist, on airway inflammation in subjects with asthma
29. 2 inhibitors on allergic pulmonary inflammation in mice
30. 4 receptor antagonist, pranlukast, or an interleukin-5 monoclonal antibody
31. 2 synthesizing enzyme, suppresses ICAM-1 expression by stimulated vascular endothelial cells
32. 2 in nonadherent human monocytes
33. 2 and E-series prostaglandins
34. Biochemical and functional differences between eosinophils from animal species and man
35. Prostaglandin and thromboxane production by human and guinea-pig macrophages and leukocytes
36. Leukotrienes and other products of 5-lipoxygenase pathway. Biochemistry and relation to pathology in human diseases